Is antimüllerian hormone an early marker or an in utero effector of incipient polycystic ovary syndrome?

Is antimüllerian hormone an early marker or an in utero effector of incipient polycystic ovary syndrome?
Even when using the strictest of diagnostic criteria, the polycystic ovary syndrome (PCOS) affects almost 1 in 10 women worldwide. Although PCOS is most clinically evident during the reproductive age, it is also clear that PCOS is a complex genetic trait with lifelong consequences. However, the presentation and impact of PCOS at each of the extremes of reproductive life, in the peripuberty and the postmenopause, remains relatively understudied and less understood. We should recognize that the study of women as they age is critical to more precisely assess their risk, and the public health impact and preventive approaches, of their associated co-morbidities such as type 2 diabetes, cardiovascular disease, and malignancies.
Source: fertstert.org